Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2020

View Archived Issues

Researchers achieve the reversal of HIV and SIV latency in vivo

Chromosome amplification drives cancer progression via effects on secretion

Fat or fiber, cFAP activation is problematic for heart

Novel panaxatriol derivative shows efficacy in rat model of MI/R injury

Phase Ia/b data presented for PL-MLP in patients with metastatic CRC

ALPN-101 demonstrates efficacy in preclinical models of chronic IBD

FDA issues clinical hold on the phase III POLAR program of PledOx

Colorectal cancer among those affected by periostin

CEPI awards funding to support development of vaccines against coronavirus 2019-nCoV

Jiangsu Hengrui Medicine, Shanghai Hengrui patent TLR8 agonists

Incyte describes new adenosine A2A and/or A2B receptor antagonists

PIKfyve inhibitors identified at MFMER, Sanford Burnham Prebys Medical Discovery Institute

Protein cereblon inhibitors discovered at Kymera Therapeutics

The University of Minnesota presents psi-glutathione compounds

PDE3A influences endothelial function and risk of ischemic stroke

Phase III study of AKP-01 spray in mild to moderate plaque psoriasis meets primary endpoint

Pivotal DESTINY-Gastric01 trial of DS-8201 meets primary endpoint

CStone begins phase III study of CS-1003 in advanced hepatocellular carcinoma

Dynacure studies DYN-101 in phase I/II trial for centronuclear myopathies

Brilinta improves outcomes after acute ischemic stroke or TIA in phase III trial

Phase I results with EPX-100 pave way for phase II studies in Dravet syndrome

Phase III BREEZE-AD4 trial of baricitinib in atopic dermatitis meets primary endpoint

Daiichi Sankyo begins phase I study in Japan with DS-2741a for atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...